We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UTHR or CTLT: Which Is the Better Value Stock Right Now?
Read MoreHide Full Article
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR - Free Report) and Catalent (CTLT - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Currently, United Therapeutics has a Zacks Rank of #2 (Buy), while Catalent has a Zacks Rank of #5 (Strong Sell). This means that UTHR's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one factor that value investors are interested in.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
UTHR currently has a forward P/E ratio of 12.93, while CTLT has a forward P/E of 49.05. We also note that UTHR has a PEG ratio of 1.40. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CTLT currently has a PEG ratio of 1.68.
Another notable valuation metric for UTHR is its P/B ratio of 2.67. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, CTLT has a P/B of 2.89.
Based on these metrics and many more, UTHR holds a Value grade of B, while CTLT has a Value grade of D.
UTHR has seen stronger estimate revision activity and sports more attractive valuation metrics than CTLT, so it seems like value investors will conclude that UTHR is the superior option right now.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
UTHR or CTLT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR - Free Report) and Catalent (CTLT - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Currently, United Therapeutics has a Zacks Rank of #2 (Buy), while Catalent has a Zacks Rank of #5 (Strong Sell). This means that UTHR's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is just one factor that value investors are interested in.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.
UTHR currently has a forward P/E ratio of 12.93, while CTLT has a forward P/E of 49.05. We also note that UTHR has a PEG ratio of 1.40. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CTLT currently has a PEG ratio of 1.68.
Another notable valuation metric for UTHR is its P/B ratio of 2.67. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, CTLT has a P/B of 2.89.
Based on these metrics and many more, UTHR holds a Value grade of B, while CTLT has a Value grade of D.
UTHR has seen stronger estimate revision activity and sports more attractive valuation metrics than CTLT, so it seems like value investors will conclude that UTHR is the superior option right now.